DOR BioPharma, Inc. Reports Positive New Survival Findings From Previously Completed Phase II And III Clinical Trials Of orBec(R)

MIAMI--(BUSINESS WIRE)--Jan. 20, 2006--DOR BioPharma, Inc. (AMEX:DOR) ("DOR", or the "Company") announced today that as part of its process to submit a New Drug Application ("NDA") for orBec(R) (oral beclomethasone dipropionate) for the treatment of patients with gastrointestinal Graft-versus-Host disease (iGVHD) and in response to a specific FDA request, it has completed an analysis to compare the statistically significant survival benefit demonstrated in favor of orBec(R) in its pivotal Phase III clinical trial to the survival results of the earlier successful 60 patient, randomized, double-blinded, placebo-controlled, Phase II clinical trial of oral beclomethasone dipropionate for iGVHD.

Back to news